PARTNER WITH US
Hanson Wade Group have taken the decision to cancel this meeting.
Please accept our apologies for any inconvenience or disappointment caused.
Why Partner?
TGF-B is a multifunctional signalling protein that is involved in cell growth, wound healing, and immune response. Therefore, in many diseases such as cancer, fibrosis, and pulmonary fibrosis, TGF-B is the ideal target for therapies. However, the pleotropic nature of TGF-B means that unspecific targeting, toxic side effects, and lack of clinical efficacy have hindered the development of TGF-B targeted therapies. The field has advanced but no TGF-B targeted therapies have been approved, due to the challenges faced by the double-edged sword nature of TGF-B.
Are you looking to partner with industry leading TGF-B-focused companies to support them in the development of safe and efficacious TGF-β targeted therapies?
The 4th TGF-B Targeted Drug Development Summit brings together industry trailblazers in different stages of development, whether it is discovery, translation, or clinical. This is your opportunity to meet big names in the industry such as Cue Biopharma, EpicentRx, Morphic, and Pfizer, and begin a collaborative partnership with them.
Experts Need Your Help with:
Discovering TGF-β specific biomarkers to follow patient response
Developing better models to aid in translation from animal to human
Toxicology & PKPD services to improve patient safety
Employing immunoassays & structural biology techniques in the discovery stage
Managing clinical trials to achieve success
Who You Can Expect to Connect With:
